Wikisage, the free encyclopedia of the second generation, is digital heritage

Brexanolone: Difference between revisions

From Wikisage
Jump to navigation Jump to search
No edit summary
No edit summary
 
(One intermediate revision by the same user not shown)
Line 6: Line 6:
''Zulresso'' i.v. for depression post partum <ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm</ref> or <ref>https://www.nytimes.com/2019/03/19/health/postpartum-depression-.html?smid=nytcore-ios-share</ref>
''Zulresso'' i.v. for depression post partum <ref>https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm</ref> or <ref>https://www.nytimes.com/2019/03/19/health/postpartum-depression-.html?smid=nytcore-ios-share</ref>


<references/>
{{refs}}


{{Wikidata|Q28487680}}
{{Wikidata|Q28487680}}
[[Category:GABAA receptor positive allosteric modulators]]

Latest revision as of 01:19, 7 May 2019

Brexanolone allotetrahydroprogesterone

  • 3α-hydroxy-5α-pregnan-20-one
  • allopregnanolone

On March 19th FDA approved Zulresso i.v. for depression post partum [1] or [2]

References

References:
  1. ↑ https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm633919.htm
  2. ↑ https://www.nytimes.com/2019/03/19/health/postpartum-depression-.html?smid=nytcore-ios-share

Q28487680 at Wikidata  Interwiki via Wikidata

Retrieved from "https://en.wikisage.org/w/index.php?title=Brexanolone&oldid=8272"